Can-Fite BioPharma (NYSE:CANF) Earns Sell Rating from Analysts at StockNews.com

Research analysts at StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research note issued to investors on Sunday. The brokerage set a “sell” rating on the stock.

CANF has been the subject of several other reports. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Can-Fite BioPharma in a research report on Tuesday, November 12th. D. Boral Capital reiterated a “buy” rating and issued a $10.00 target price on shares of Can-Fite BioPharma in a research report on Tuesday, December 31st.

Can-Fite BioPharma Stock Performance

Shares of CANF stock opened at $1.56 on Friday. The company has a market capitalization of $5.52 million, a PE ratio of -0.87 and a beta of 1.36. Can-Fite BioPharma has a 52-week low of $1.29 and a 52-week high of $4.69. The business’s fifty day moving average is $1.67 and its 200 day moving average is $2.22.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.